SHINE Technologies Raises $240M in Equity Funding

Some companies raise capital. Others generate it. SHINE Technologies just did both. In a world obsessed with software margins and overnight unicorns, Greg Piefer chose neutrons. Not the sexy kind that trend on X, but the kind that split atoms, power diagnostics, and quietly decide whether a cancer patient gets treated on time. That is conviction with a lab coat on.

SHINE Technologies closed $240M in new equity funding, pushing total capital raised north of $1B. Let that settle in. 9 zeros behind a thesis that fusion is not a science fair project but a commercial engine. Leading the round is Dr. Patrick Soon-Shiong, founder of NantWorks, who also joins the Board of Directors. When a surgeon-scientist who has built billion-dollar biotech platforms leans into your neutron stream, that is not a polite nod. That is strategic gravity.

Fidelity Management & Research Company, Sumitomo Corporation of Americas, Pelican Energy Partners, Deerfield Management, Oaktree Capital Management and other existing investors doubled down. Smart capital does not chase hype in nuclear. It studies half-life. It measures throughput. Then it wires the funds.

Greg Piefer, Founder and CEO, has been methodical about this build. Start with medical isotopes. Produce what hospitals actually need. Scale Lu-177 to power targeted cancer therapies. Expand neutron testing for defense and aerospace where mission critical is not a metaphor. Then reinvest that revenue into the longer arc: recycling nuclear fuel and advancing fusion energy itself. Cash flow as rocket fuel. Patience as strategy.

Ross Radel, CTO, is pushing the physics forward. Eli Moll, COO, is turning complex science into operational muscle. This is not theory floating in a white paper. This is hardware in Wisconsin, systems humming, isotopes shipping, customers depending.

The NantWorks partnership includes $150M tied to priority access for Lu-177. Translation: supply chain meets survival rate. In a market where isotope shortages have been a recurring headline, SHINE Technologies is building domestic resilience with fusion at the core. Shine by name, sure. But also by design.

The lesson for founders is not “go build a fusion company.” The lesson is build where the pain is undeniable and the moat is physics deep. Solve real constraints. Align with investors who understand the stack from molecule to market. Raise capital as a consequence of traction, not theater.